LI
NBIX icon

Leap Investments’s Neurocrine Biosciences NBIX Stock Holding History

Leap Investments’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-19,500
Closed -$2.1M – 495
2019
Q4 		$2.1M Buy
+19,500
New +$2.04M 0.98% 6

Other funds holding NBIX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Leap Investments's NBIX Position: Q1 2020 in Review

Leap Investments sold out of Neurocrine Biosciences (NBIX) in Q1 2020, closing a stake of 19,500 shares — an estimated $2.1M sold.

Leap Investments first reported a position in NBIX in Q4 2019 and held it in 1 quarter. The position peaked at $2.1M in Q4 2019. 368 funds tracked by Wall St. Rank hold NBIX as of Q1 2020.

  • Leap Investments reported no remaining Neurocrine Biosciences position as of Q1 2020 after selling out during the quarter.
  • Leap Investments sold 19,500 Neurocrine Biosciences shares in Q1 2020, an estimated $2.1M.
  • Leap Investments first reported a position in Neurocrine Biosciences in Q4 2019 and held it in 1 quarter.
  • Leap Investments's Neurocrine Biosciences position peaked at $2.1M in Q4 2019.
  • 368 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2020.

Based on Leap Investments's 13F filing for Q1 2020, filed 15 May 2020.